In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the existence of gene mutations based on images of leukemia cells.

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density neutrophil subsets in myelodysplastic syndromes (MDS), acute myeloid leukemia ...

Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of ...

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...

Acute myeloid leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer. This study explores the role of ...